Cyclo Therapeutics, Inc. (CYTH)
Cyclo Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Gainesville, FL, US. The stock last traded at $0.72, up 0.00% on the session, giving a market capitalisation of $23.6M. On trailing twelve-month figures it carries a trailing P/E of -0.59, a net margin of -1863.4%. Its beta of -0.57 implies it has historically moved less than the broad market.
Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease. The company is also investigating Trappsol Cyclo's efficacy in addressing Alzheimer's disease. Beyond its drug development pipeline, the firm engages in the sale of cyclodextrins and related commodities to sectors such as pharmaceuticals and nutrition, primarily for their application in diagnostics and specialized drug formulations. Originally established in 1990 as CTD Holdings, Inc., the company adopted its current name, Cyclo Therapeutics, Inc., in September 2019 and maintains its headquarters in Gainesville, Florida.
Cyclo Therapeutics, Inc. is most often compared with the following Healthcare names: